Goldman Sachs
MTNB icon

Goldman Sachs’s Matinas BioPharma MTNB Stock Holding History

Goldman Sachs’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-704
Closed -$17.6K – 6126
2022
Q4 		$17.6K Buy
+704
New +$23.4K ﹤0.01% 5711
2022
Q1 		– Sell
-929
Closed -$47K – 6789
2021
Q4 		$47K Buy
+929
New +$49.7K ﹤0.01% 6277
2021
Q2 		– Sell
-430
Closed -$23K – 6399
2021
Q1 		$23K Buy
+430
New +$28.8K ﹤0.01% 6003
2020
Q2 		– Sell
-4,861
Closed -$146K – 5382
2020
Q1 		$146K Buy
4,861
+3,119
+179% +$188K ﹤0.01% 4822
2019
Q4 		$198K Buy
+1,742
New +$101K ﹤0.01% 4898
2019
Q2 		– Sell
-1,208
Closed -$66K – 5279
2019
Q1 		$66K Buy
+1,208
New +$65.1K ﹤0.01% 4978
2018
Q4 		– Sell
-5,667
Closed -$261K – 5515
2018
Q3 		$261K Sell
5,667
-4,047
-42% -$87K ﹤0.01% 4784
2018
Q2 		$211K Buy
9,714
+9,406
+3,054% +$272K ﹤0.01% 4973
2018
Q1 		$12K Sell
308
-783
-72% -$41.4K ﹤0.01% 5728
2017
Q4 		$63K Buy
1,091
+690
+172% +$44.4K ﹤0.01% 5885
2017
Q3 		$26K Buy
401
+182
+83% +$12.1K ﹤0.01% 6391
2017
Q2 		$18K Sell
219
-4,215
-95% -$566K ﹤0.01% 6577
2017
Q1 		$614K Buy
+4,434
New +$723K ﹤0.01% 4827

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Goldman Sachs's MTNB Position: Q1 2023 in Review

Goldman Sachs sold out of Matinas BioPharma (MTNB) in Q1 2023, closing a stake of 704 shares — an estimated $17.6K sold.

Goldman Sachs first reported a position in MTNB in Q1 2017 and held it in 13 quarters. The position peaked at $614K in Q1 2017. 50 funds tracked by Wall St. Rank hold MTNB as of Q1 2023.

  • Goldman Sachs reported no remaining Matinas BioPharma position as of Q1 2023 after selling out during the quarter.
  • Goldman Sachs sold 704 Matinas BioPharma shares in Q1 2023, an estimated $17.6K.
  • Goldman Sachs first reported a position in Matinas BioPharma in Q1 2017 and held it in 13 quarters.
  • Goldman Sachs's Matinas BioPharma position peaked at $614K in Q1 2017.
  • 50 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.